PCM
UTHR icon

Penn Capital Management’s United Therapeutics UTHR Stock Holding History

Penn Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,613
Closed -$2.15M – 164
2023
Q4 		$2.15M Sell
9,613
-621
-6% -$143K 0.2% 98
2023
Q3 		$2.35M Sell
10,234
-63
-0.6% -$14.5K 0.24% 99
2023
Q2 		$2.27M Buy
10,297
+16
+0.2% +$3.54K 0.22% 101
2023
Q1 		$2.36M Sell
10,281
-1,045
-9% -$258K 0.24% 100
2022
Q4 		$3.2M Buy
11,326
+596
+6% +$150K 0.33% 81
2022
Q3 		$2.29M Buy
10,730
+1,838
+21% +$411K 0.26% 99
2022
Q2 		$2.1M Buy
8,892
+932
+12% +$189K 0.23% 105
2022
Q1 		$1.43M Sell
7,960
-416
-5% -$79.3K 0.15% 149
2021
Q4 		$1.75M Sell
8,376
-316
-4% -$62K 0.18% 146
2021
Q3 		$1.6M Buy
8,692
+84
+1% +$16.5K 0.16% 152
2021
Q2 		$1.54M Buy
+8,608
New +$1.64M 0.15% 162

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Penn Capital Management's UTHR Position: Q1 2024 in Review

Penn Capital Management sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 9,613 shares — an estimated $2.15M sold.

Penn Capital Management first reported a position in UTHR in Q2 2021 and held it in 11 quarters. The position peaked at $3.2M in Q4 2022. 526 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • Penn Capital Management reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Penn Capital Management sold 9,613 United Therapeutics shares in Q1 2024, an estimated $2.15M.
  • Penn Capital Management first reported a position in United Therapeutics in Q2 2021 and held it in 11 quarters.
  • Penn Capital Management's United Therapeutics position peaked at $3.2M in Q4 2022.
  • 526 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on Penn Capital Management's 13F filing for Q1 2024, filed 15 May 2024.